Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck's CETP inhibitor meets primary endpoint

MRK said anacetrapib ( MK-0859) met the primary endpoint of a significant reduction in LDL-C vs. placebo in

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE